Report of Foreign Issuer (6-k)
2012年12月11日 - 2:54AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of December 2012
Commission File Number: 1-32186
(Translation of registrant's name into English)
|
|
Suite 400, Building 11
5045 Orbiter Drive
Mississauga, Ontario
Canada L4W 4Y4
|
(Address of principal executive offices)
|
Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1)
o
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7)
o
DOCUMENTS FILED
See the Exhibit Index hereto.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
YM BIOSCIENCES INC.
|
|
|
|
|
|
By:
|
/s/ Leonard Vernon
|
|
|
Leonard Vernon
Vice President, Finance and Administration
|
Date: December 10, 2012
EXHIBIT INDEX
Exhibit
|
|
Description
|
|
|
|
99.1
|
|
News Release Dated December 9, 2012 - YM BioSciences Reports Phase I/II Data for JAK Inhibitor CYT387 in Myelofibrosis at ASH 2012
|
YM Biosciences (AMEX:YMI)
過去 株価チャート
から 9 2024 まで 10 2024
YM Biosciences (AMEX:YMI)
過去 株価チャート
から 10 2023 まで 10 2024
Real-Time news about YM Biosciences Ordinary Shares (Canada) (アメリカ証券取引所): 0 recent articles
その他のYm Biosciences Incニュース記事